Skip to main content

Advertisement

Table 5 Comparative analysis of integrative genomic approach and cancer panels. The numbers corresponding to the three cancer panels are hypothetical (based on the panel design) and not based on experimental results

From: Development and clinical application of an integrative genomic approach to personalized cancer therapy

Genomic approach Mean number of cancer-relevant somatic mutations (range) Number of patients with tier 1 drug recommendations Number of patients with tier 2 drug recommendations Number of patients with actionable alterations Mean number of actionable alterations (range)
Ion AmpliSeq Cancer Hotspot Panel v2 1.3 (0–4) 24 (52 %) 16 (35 %) 24 (52 %) 0.65 (0–3)
Oncomine Comprehensive Panel 2.5 (0–11) 39 (85 %) 24 (52 %) 41 (89 %) 2.4 (0–6)
FoundationOne 3.7 (0–22) 39 (85 %) 24 (52 %) 41 (89 %) 2.6 (0–7)
This study 17.3 (1–79) 40 (87 %) 26 (57 %) 42 (91 %) 4.9 (0–14)